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Most neurodegenerative disorders are associated with accumulation of disease-relevant proteins. Among them, 
Huntington disease (HD) is of particular interest because of its monogenetic nature. HD is mainly caused by cyto-
toxicity of the defective protein encoded by the mutant Huntingtin gene (HTT). Thus, lowering mutant HTT protein 
(mHTT) levels would be a promising treatment strategy for HD. Here we report two kinases HIPK3 and MAPK11 
as positive modulators of mHTT levels both in cells and in vivo. Both kinases regulate mHTT via their kinase activ-
ities, suggesting that inhibiting these kinases may have therapeutic values. Interestingly, their effects on HTT levels 
are mHTT-dependent, providing a feedback mechanism in which mHTT enhances its own level thus contributing to 
mHTT accumulation and disease progression. Importantly, knockout of MAPK11 significantly rescues disease-relevant 
behavioral phenotypes in a knockin HD mouse model. Collectively, our data reveal new therapeutic entry points for 
HD and target-discovery approaches for similar diseases.
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Introduction
Neurodegenerative disorders are devastating diseases 
caused by progressive loss of neurons in the central ner-
vous systems. They influence millions of people, espe-
cially in the aged population. Treatment of such diseases 
has been extremely challenging, due to the complexity 
of their diagnosis and pathogenic mechanisms [1]. On 
the other hand, many types of neurodegenerative disor-
ders share the common feature of the accumulation of 
misfolded and aggregation-prone proteins, and lowering 
the levels of these proteins is considered as an appealing 
therapeutic strategy [2]. This strategy is likely to be more 
effective in inherited monogenetic neurodegenerative 
diseases, because the casual relationships between the 
mutant proteins and the diseases are clear: the mutant 
proteins encoded by these mutated genes are more likely 
to be the causes rather than the consequences of the dis-
eases. In addition, the patients can be diagnosed earlier, 
offering the possibility of preventative treatment.
Thus, Huntington’s disease (HD) represents an im-
portant model for neurodegenerative disorders because 
of its monogenetic nature. HD is caused by the mutation 
of the Huntingtin (HTT) gene, which encodes the mutant 
HTT protein (mHTT) with an expanded polyglutamine 
tract (polyQ) [3]. The gain of toxic function of mHTT is 
the major cause of HD, but the molecular mechanisms 
are unclear and likely involve multiple pathways [4], 
which are highly challenging to target simultaneously. 
On the other hand, lowering mHTT protein levels has 
been shown to effectively mitigate mHTT toxicity: in an 
HD mouse model expressing inducible mHTT N-termi-
nal fragments, turning off transgene expression reversed 
neuropathology and motor deficits [5]; in several mam-
malian models, delivery of short hairpin RNAs or small 
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interference RNAs (siRNAs) or antisense oligonucle-
otides (ASOs) against mHTT attenuate neuropathology 
and disease-related phenotypes [6-9]. Screening studies 
also revealed genetic and chemical modifiers that reduce 
mHTT aggregates and rescue HD-relevant phenotypes 
[10]. Recent studies have also shown that the level of 
soluble mHTT is closely related with disease pathology 
[11-13], and thus lowering soluble mHTT may provide 
an effective approach to treat HD by ameliorating any 
downstream toxicity. If successful, this strategy is able 
to modify disease progression, and similar strategies 
could be applied to other diseases as well [14]. Previous 
mHTT-lowering studies are mostly based on RNA in-
terference (RNAi) or ASOs. However, it is challenging 
to deliver such reagents to the affected brain regions of 
HD patients. Thus, druggable targets for low-molecu-
lar weight compounds that can lower mHTT levels are 
highly desired. Meanwhile, the wild-type HTT protein 
(wtHTT) is an essential protein during development [15, 
16] and may also play a role in HD [17] and lowering 
wtHTT to an intolerable extent may have a harmful im-
pact. Thus, the wtHTT levels and phenotypic outcomes 
need to be carefully evaluated in any strategy based upon 
lowering of HTT levels.
Here, we report an unbiased RNAi screen that reveals 
the kinases MAPK11 and HIPK3 as novel modulators 
of mHTT protein levels. Both kinases influence mHTT 
levels via their kinase activities; opening up new drug 
discovery opportunities. We further validated the effect 
of MAPK11 and HIPK3 in vivo in an HD knockin (KI) 
mouse model, and confirmed their therapeutic potentials 
in lowering mHTT levels.
Results
Unbiased screen reveals genetic modulators of mHTT 
levels
To reveal druggable modulators of mHTT levels, we 
performed an RNAi screen (Figure 1A) using a focused 
siRNA library (regulome) targeting 2 666 genes express-
ing proteins (mostly enzymes and receptors) that belong 
to the protein families that are capable of regulating pro-
tein levels. The screen was performed in immortalized 
HD patient fibroblasts from two independent patients 
(Q45 and Q68) expressing endogenous full-length hu-
man mHTT proteins. mHTT levels were measured by the 
homologous time-resolved fluorescence (HTRF) assay 
using the 2B7/MW1 antibody pair which selectively 
detects mHTT [18] (Supplementary information, Figure 
S1). The HTRF assay utilizes a terbium-conjugated an-
tibody (donor) and a D2-conjugated antibody (acceptor) 
targeting the same protein; time-resolved fluorescence 
resonance energy transfer [19] occurs when the two anti-
bodies come into close proximity by binding with a com-
mon protein molecule. As a result, the HTRF signals are 
proportional to the target protein concentration and can 
be used to quantify its level [20]. This technology has 
been successfully applied to the measurement of HTT 
levels in previous studies [21, 22].
The genes with at least two (out of four) independent 
siRNAs that reduced mHTT more than 20% in both lines 
without reducing the cell number by more than 5% (mea-
sured by cell titer-glo) were selected as candidate hits. 
Genes that are not expressed in the human brain based on 
the BioGPS database [23] and the Allen Brain Atlas [24] 
were excluded. The remaining preliminary hits (Figure 
1B) were then tested in a human neuronal HD model [13] 
for phenotypic validation (Figure 1C-1F). These neurons 
were derived from human embryonic stem-cells (hESC) 
stably expressing mHTT-exon1 (Q73) fragment and 
exhibited a mHTT-dependent neuronal loss phenotype 
(measured by cell confluence) under standard non-pro-
tective culture conditions [13] (Figure 1C). The prelimi-
nary hits were tested by transfecting siRNA-pools target-
ing these hits in 96-well plates with biological duplicates 
(Figure 1D). The cultures exhibited substantial differenc-
es in neuronal survival, which negatively correlated with 
the mHTT-exon1 Q73 levels measured by HTRF (Figure 
1E). This is consistent with the expectation that changing 
mHTT levels via the modifiers influences the survival of 
HD neurons. 11 out of the 19 preliminary hits showed 
obvious rescue of survival in this neuronal model (Figure 
1F).
MAPK11 and HIPK3 regulate endogenous mHTT levels
Among the 11 identified putative mHTT modula-
tors, we found a clustering of MAPK-related proteins: 
MAP2K6 and MAPK11 that belong to the same sig-
naling pathway, in which MAP2K6 phosphorylates 
MAPK11 [25]; HIPK3, which is regulated by JNK1 and 
JNK2 (also referred to as MAPK8 and MAPK9) [26]. 
The enrichment of genes for MAPK-related proteins 
suggested that these kinases may have a higher chance 
of being reliable mHTT modulators and we therefore 
prioritized MAPK11, MAP2K6 and HIPK3 for further 
validation. 
We first validated these targets in the mouse HD 
striatal cell line STHdhQ7/Q111 [27], a well-established 
cellular model which expresses endogenous full-length 
mHtt (the mouse homolog of human mHTT) with 111Q. 
The HTRF assay utilizing the 2B7/MW1 antibody pair 
does not work properly in STHdh cells. Moreover, the 
2B7/2166 antibody pair works well but detects the total 
signals from both mHtt and the wtHtt [28]. Thus, we 
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first validated these targets by western blots instead of 
using HTRF in STHdh cells. Knocking down these tar-
gets using siRNAs (Supplementary information, Figure 
S2A-S2C) significantly reduced the endogenous level of 
soluble full-length mHtt (Figures 2A and 4A) in HD cells 
(Q7/Q111). The reduction in mHtt did not appear to re-
sult from cleavage changes, because no increase of mHtt 
fragments at lower molecular weights was observed 
(Supplementary information, Figure S2D). 
To further validate these targets in HD models in 
which HTT has a polyQ length equivalent to that more 
commonly found in HD patients, we tested these targets 
in Q47 human induced-pluripotent-stem cell (iPSC)-de-
rived neurons expressing endogenous mHTT with 47Q 
[29]. We chose to use the 2B7/MW1 HTRF assay (Sup-
plementary information, Figure S1), which is a more 
accurate and reliable way of measuring mHTT in these 
cells [29, 30]. Knocking down these targets by siRNAs 
(Supplementary information, Figure S2A-S2C) reduced 
the endogenous soluble mHTT levels in these iPSC-de-
rived neurons (Q47 neurons) (Figure 2B), confirming 
their value in the human HD neuronal model expressing 
mHTT with 40-50Q, a polyQ length most commonly 
found in HD patients. 
We then triaged the targets by validating their effects 
on mHtt levels in mouse models in vivo. MAP2K6 is an 
upstream activator of MAPK11, its major downstream 
effector. Thus, MAP2K6 may regulate mHTT through 
MAPK11. In accord with this, knockdown of Mapk11 
diminished the Map2k6-mediated effect on mHTT levels 
in STHdhQ7/Q111 cells (Supplementary information, Figure 
S3A). This epistasis effect is in agreement with Mapk11 
being downstream of Map2k6. In addition, Map2k6 
knockout results in immune defects and delay in testis 
determination [31]. Therefore, considering that in vivo 
validations are highly time-consuming and resource-con-
suming, we prioritized MAPK11 and HIPK3 for in vivo 
validation. 
 We confirmed that MAPK11 and HIPK3 are ex-
pressed in both human and mouse brains (Supplementary 
information, Figure S3B-S3E). We then generated the 
Mapk11 and Hipk3 knockout mice by TALEN technol-
ogy (see Materials and Methods section), respectively 
(Supplementary information, Figure S4A and S4B). Both 
types of mice were born in a roughly Mendelian ratio 
(Hipk3: 21% −/−, 23% +/+ and 56% +/−, from 111 mice; 
Mapk11: 25% −/−, 23% +/+ and 52% +/−, from 295 
mice) and were viable and fertile and of normal appear-
ance/weight/size/major tissue size and weight, and had 
no obvious health problems when kept under standard 
specific-pathogen-free conditions, consistent with pre-
vious reports [32, 33]. We crossed them to a well-estab-
lished HD KI mouse model expressing endogenous mHtt 
proteins with a 140Q repeat [34]. Heterozygous knock-
out of Hipk3 or Mapk11 significantly lowered full-length 
Htt levels in vivo in the striata of the HD mice (HdhQ140/
Q7, Figure 2C and 2D). Noticeably, heterozygous Hipk3 
knockout mice had lower Htt levels at 10 months of age 
but not at 5 months old (not shown), possibly because 
Hipk3 expression level is higher in HD only at later ages 
(Figure 3D).
To test whether Mapk11 or Hipk3-mediated Htt regu-
lation is specific, we tested a number of control proteins 
including β-actin, Gapdh, Calnexin, Tuj1, Map2, α-tubu-
lin and β-tubulin. None of their levels were significantly 
reduced in Mapk11 or Hipk3 knockout mice (Supple-
Figure 1 Potential druggable genetic modifiers of mHTT levels identified by screening. (A) A schematic flowchart showing the 
screening process. (B) The information of potential preliminary hits. mHTT levels were measured by HTRF using the 2B7/
MW1 antibody pair in two different human HD patient fibroblast lines (Q68 versus Q45). “# of mHTT lowering siRNAs” indi-
cates the number of siRNAs (out of four) that reduce mHTT levels in both lines. (C) When cultured under standard (non-pro-
tective) conditions, hESC-derived neurons stably expressing HTT-exon1 fragments exhibited a long polyQ (Q73) specific de-
generation phenotype, which could be assessed by imaging-based measurements. Representative images (of over 20 biolog-
ical replicates) show the neuronal survival changes in these cells (Q73 neurons) transfected with scrambled siRNA (scramble) 
or HTT-exon1 siRNA (HTT). Scale bar, 50 µm. (D) The candidate hits were tested in Q73 neurons using SMART-pool siRNAs 
(Dharmacon) and the confluences measured by imaging at different time points were calculated by IncuCyte based on four 
fields in each well. The signals from two independent transfections (Plate A versus B) show consistency, signals are clustered 
near the diagonal line (red). (E) In Q73 neurons transfected with siRNA-pools targeting the primary hits, the averaged conflu-
ences of wells transfected with each siRNA in each plate were plotted with the mHTT-exon1 levels (eight measurements from 
two independent transfected wells) and measured by HTRF using the 2B7/MW1 antibody pair 48 h after transfection. The 
correlation coefficient R and P values for confluences measured at 68 h were calculated by Spearman correlation analysis. (F) 
Neuronal survival plots of Q73 neurons transfected with indicated siRNAs. Neuronal survival was measured by the averaged 
confluence of four fields in each well. Note that the scramble and the HTT siRNA signals of all these plots are from the same 
samples tested in parallel with the candidate genes. The scrambled (n = 16) and HTT siRNA (n = 4) plots represent mean 
and SEM, whereas each of the two independently transfected wells of the hits are plotted individually. The genes targeted by 
siRNAs that obviously increased neuronal survival (higher survival at all the time points measured) were selected as potential 
hits.
Meng Yu et al.
1445
www.cell-research.com | Cell Research | SPRINGER NATURE
1446
MAPK11 and HIPK3 regulate mutant Huntingtin
SPRINGER NATURE | Cell Research | Vol 27 No 12 | December 2017
mentary information, Figure S5A-S5D). Of other polyQ 
proteins including ataxin1, 2&3, we could only detect 
ataxin3 expression in our models and its levels were not 
reduced in the Mapk11 or Hipk3 knockout mice (Supple-
mentary information, Figure S5A-S5D). Taken together, 
these results suggest that the effects of Mapk11 and 
Hipk3 on the mHtt levels are specific.
Both MAPK11- and HIPK3-mediated effects on HTT lev-
els are mHTT-dependent
Interestingly, we found that both the MAPK11- and 
HIPK3-mediated effects occurred only in HD, but not in 
wild-type (WT) cells/tissues (Figure 2). Two possibili-
ties may account for this observation. First, the regula-
tion of HTT by these kinases might be mHTT-specific, 
i.e., MAPK11 and HIPK3 only regulate mHTT but not 
wtHTT. Second, the regulation is mHTT-dependent, 
i.e., both mHTT and wtHTT levels are regulated by 
MAPK11/HIPK3 only in presence of mHTT. The second 
possibility seems to be the case, because both the wtHTT 
and mHTT levels appeared to be lowered similarly in the 
HD cells or tissues (Supplementary information, Figure 
S6A and S6B). To further clarify the mHTT-dependence, 
we expressed the mHTT-exon1 (Q72) fragment [35] 
in WT cells (STHdhQ7/Q7) (Supplementary information, 
Figure S6C), in which the wtHtt level is insensitive to 
Mapk11 or Hipk3 (Figure 2A). The regulation of the 
wtHtt level by Mapk11 or Hipk3 was then enabled in 
the presence of mHTT-exon1 (Q72) but not wtHTT-ex-
on1 (Q25) protein fragments (Figure 3A and 3B). This 
suggests that mHTT is sufficient to drive the Mapk11/
Hipk3-mediated modulation of Htt that is absent in WT 
cells. This effect is dependent on mHTT, because ex-
pression of the long polyQ itself (Q72-GFP) or another 
polyQ protein (Atxn1 (Q92)) did not have such effects 
(Supplementary information, Figure S6D). Moreover, we 
specifically knocked down mHtt in the STHdhQ7/Q111 cells 
with an allele-specific siRNA that selectively lowers 
mHtt via targeting the CAG repeat region [36-38], and 
the Mapk11/Hipk3-mediated modulation of both mHtt 
and wtHtt was diminished (Figure 3C); suggesting that 
mHTT is required for this regulation. Taken together, this 
indicates that MAPK11/HIPK3-mediated HTT modula-
tion is dependent on the presence of mHTT proteins: in 
WT cells without mHTT or in HD cells in which mHTT 
is knocked down, MAPK11/HIPK3-mediated regulation 
of HTT is largely absent and thus the HTT level is insen-
sitive to these kinases (Figures 2 and 3C); in HD cells 
with mHTT or in WT cells with exogenously expressed 
mHTT-exon1 fragments, the MAPK11-mediated and 
HIPK3-mediated HTT regulation is enabled, and both 
the mHTT and wtHTT levels become sensitive to these 
kinases (Figures 2, 3A and 3B). 
Our observation of mHTT-dependent HTT modula-
tion suggests that mHTT may enhance its own level by 
enabling positive regulation mediated by MAPK11 and 
HIPK3, which may contribute to disease progression. 
mHTT may confer positive effects on MAPK11 and 
HIPK3
Since mHTT is required for the MAPK11/HIPK3-me-
diated effects, we speculate that mHTT may elevate the 
levels or activities of MAPK11 or HIPK3, granting them 
the capability of regulating HTT levels. Indeed, mHTT 
has been shown to activate p38 MAPKs and c-Jun N-ter-
minal kinases (JNKs) [39]. MAPK11 is a family member 
of the p38 MAPKs, which are activated by mHTT. The 
HIPK3 mRNA level is elevated by JNKs [26], which are 
also activated by mHTT. Thus, these previous results 
suggest that mHTT may activate MAPK11 kinase activ-
Figure 2 HIPK3 and MAPK11 regulate HTT levels. (A) Left panels, representative western blots for the indicated proteins in 
STHdh cells upon transfection of the indicated siRNAs. Note that ab1 (N terminal antibody) detects both mHtt and wtHtt, and 
MW1 (polyQ antibody) detects mHtt only. Knocking down Hipk3 or Mapk11 reduces Htt levels in the HD (Q7/Q111) cells but 
not the WT (Q7/Q7) cells; Right panels, quantifications of the western blots. Hdh5 is an siRNA directly targeting the mouse 
Htt gene. (B) Left, A representative image showing the HD patient iPSC-derived neurons (blue, DAPI; green, Tuj1; scale bar, 
50 µm); middle, mHTT levels of the HD patient iPSC-derived neurons measured by HTRF using the 2B7/MW1 antibody pair 
that detects mHTT specifically. Right, wtHTT levels of the control patient iPSC-derived neurons measured by HTRF using the 
2B7/2166 antibody pair. (C) Representative western blots and quantifications showing that heterozygous deletion of Hipk3 
reduces endogenous Htt levels in the striata of 10-month-old HD (HdhQ140/Q7) mice, but not WT (HdhQ7/Q7) mice. For quantifica-
tions, the Htt signal (measured by ab1) were first normalized to the loading control (β-Tubulin). The loading control corrected 
signals were then normalized to the average of WT controls at the same age. (D) Representative western blots and quantifi-
cations showing that heterozygous deletion of Mapk11 reduces endogenous Htt levels in the striata of 4- and 6.5-month-old 
HD (HdhQ140/Q7) mice, but not in WT (HdhQ7/Q7) mice. The quantification is the same as (C). For all bar plots in this figure, all 
signals were normalized to the average signal of the scrambled siRNA-transfected controls; the bars were plotted as mean 
and SEM; the number on top of each indicates the number of biological replicates, and the statistical analysis was performed 
by one-way ANOVA and post hoc Dunnett’s tests for A and B, and two-way unpaired t tests for C and D, compared to the 
scramble siRNA-transfected control. *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05.
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ity and elevate the HIPK3 mRNA level, conferring upon 
them the ability to regulate HTT levels.
In accord with this, the endogenous Hipk3 mRNA 
level was significantly higher in HD cells (STHdhQ7/Q111) 
than in WT cells (STHdhQ7/Q7) as determined by qRT-
PCR (Figure 3D, left). A similar phenomenon was also 
observed in vivo in the striata of HD mice (HdhQ140/Q7) 
compared to WT controls (HdhQ7/Q7) at the age of 6-8 
months (Figure 3D, right), in line with previous reports 
in human brain tissues, where the HIPK3 expression is 
~33% higher in HD patients versus controls [40]. Notice-
ably, this difference was not present at earlier ages (2-4 
months) (Figure 3D, middle), suggesting that mHtt may 
increase the expression of Hipk3 as the disease progress-
es. To further establish the relationship between mHTT 
and Hipk3 levels, we knocked down Htt (both mHtt and 
wtHtt) in HD cells (STHdhQ7/Q111), or wtHtt in WT cells, 
and measured Hipk3 mRNA levels. The Hipk3 mRNA 
levels are significantly reduced by lowering Htt in HD 
cells but not by lowering wtHtt in WT cells (Figure 3E). 
This confirms the positive regulation of Hipk3 mRNA 
level by mHtt but not wtHtt. A similar phenomenon was 
observed in patient iPSC-derived neurons (Figure 3F). 
We observed no increase of Mapk11 mRNA levels in HD 
cells (STHdhQ7/Q111) compared to the WT cells (STHdhQ7/
Q7) (Supplementary information, Figure S6E, left), and 
a marginal but insignificant increase in the striata of HD 
mice (HdhQ140/Q7) compared to WT controls (HdhQ7/Q7) 
(Supplementary information, Figure S6E, right), suggest-
ing that mHtt could enhance kinase activity rather than 
the Mapk11 level. Consistent with this, over-expression 
of mHTT (HTTexon1 (Q72)) but not wtHTT (HTTexon1 
(Q25)) increased the phosphorylation of MAPK11 de-
tected by the phospho-p38 MAPK antibody (Figure 3G). 
MAPK11 was over-expressed in this experiment due to 
a lack of specific antibody-detecting endogenous phos-
phor-MAPK11. To confirm activation of endogenous 
MAPK11, we assessed its ability to phosphorylate Atf2 
[41]. We found that Atf2 phosphorylation was signifi-
cantly reduced in the striata of Mapk11 knockout mice 
(Figure 3H), confirming Atf2 as a Mapk11 substrate. 
Interestingly, Atf2 phosphorylation was significantly in-
creased in the striata of HD mice (HdhQ140/Q7) compared 
to WT controls (HdhQ7/Q7) (Figure 3I), suggesting that 
Mapk11’s kinase activity was enhanced in HD cells. 
The enhancement of MAPK11 kinase activity by mHtt 
is could be partially contributed by elevated oxidative 
stress, because lowering the oxidative stress by treatment 
of the NADPH oxidase inhibitor diphenyleneiodonium 
chloride (DPI) [42] significantly decreased mHTT-in-
duced MAPK11 phosphorylation (Figure 3G).
Collectively, our data reveal the positive feedback reg-
ulation of HTT mediated by MAPK11 or HIPK3. While 
this may not be the only mechanism for their mHTT-de-
pendent effects, it suggests a mechanism through which 
mHTT enhances its own level and thus contributes to its 
Figure 3 HIPK3- and MAPK11- mediated HTT regulation is mHTT-dependent. (A) Representative western blots and quan-
tification of the STHdhQ7/Q7 (WT) cells showing that expression of the mHTT (Q72) but not the wtHTT (Q25) N-terminal exon1 
fragments enables the reduction of endogenous wtHtt levels by knocking down Mapk11. The wtHtt change by the siRNA target-
ing Mapk11 was calculated within each group of cDNA transfected samples and plotted as the percentage difference between 
each of the Mapk11 siRNA-transfected well and the average of the scramble siRNA-transfected control within the same group. 
The statistical analysis was performed by one-way ANOVA and Dunnett’s post hoc tests. (B) Similar to (A), but showing the 
effects of knocking down Hipk3. (C) Representative western blots and quantifications (by ab1) of the HD (STHdhQ7/Q111)  cells 
showing that specifically knocking down mHtt using the allele-specific siRNA (allele specific mHtt si) abolished the reduction 
of endogenous Htt levels by knocking down Mapk11 or Hipk3. The statistical analysis was performed by two-tailed unpaired 
t tests. (D) qPCR measurements of Hipk3 mRNA levels in the HD (Q7/Q111) versus the WT (Q7/Q7) STHdh cells (left), and 
in the HD (HdhQ140/Q7) versus the WT (HdhQ7/Q7) mouse striata of animals at indicated ages (middle and right). The levels were 
normalized to the average of WT samples. The statistical analysis was performed by two-tailed unpaired t tests. (E) qPCR 
measurements of Hipk3 mRNA levels in the HD (STHdhQ7/Q111) cells or the WT (STHdhQ7/Q7) cells transfected with the indicat-
ed siRNAs. B01, C01 and Hdh5 are siRNAs targeting Htt (see Supplementary information, Data S1). The levels were normal-
ized to the average of scrambled siRNA-transfected control samples (Scramble), and the statistical analysis was performed 
by one-way ANOVA followed by post hoc Dunnett’s tests. (F) Similar to (E), but in patient iPSC-derived neurons. HTT3 is 
the siRNA targeting human HTT. (G) Representative western blots and quantifications of phospho-MAPK11/MAPK11 ratio in 
STHdhQ7/Q7 WT cells transfected with indicated cDNA and treated with indicated compounds. The p-MAPK11/MAPK11 ratio 
change compared to the Mock control was quantified to assay the activation of MAPK11. (H) Western blots and quantification 
of Atf2 and phosphorylated Atf2 (p-Atf2) levels in striata lysates from 6.5-month-old mice with or without Mapk11 knockout in 
the wild-type background using specific antibodies targeting Atf2 versus phosphorylated Atf2, respectively. Atf2 phosphory-
lation was significantly decreased in Mapk11 knockout mice, confirming Atf2 as a substrate for Mapk11. Statistical analysis 
was performed by two-tailed unpaired t tests. (I) Similar to (H), but comparing HD (HdhQ7/Q140) versus WT mice (HdhQ7/Q7). Atf2 
phosphorylation was significantly increased in HD mice, suggesting that Mapk11 activity may be increased. For all plots, error 
bars represent mean and SEM. *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05.
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In summary, MAPK11 and HIPK3 regulate HTT 
through their kinase activities, opening up possibilities 
for HD drug development.
MAPK11 regulates HTT mRNA stability while HIPK3 
regulates HTT degradation via autophagy 
In mouse striatal HD cells (STHdhQ7/Q111) but not WT 
cells (STHdhQ7/Q7), Htt mRNA was significantly reduced 
by knocking down Mapk11 (Figure 5A, statistics on 
right), and this showed a significant positive correlation 
with Mapk11 mRNA levels (Figure 5A, statistics on 
top). Similar phenomena were observed in HD patient 
iPSC-derived Q47 neurons and HD mouse (HdhQ7/Q140) 
striata (Figure 5B and 5C), suggesting that MAPK11 
positively regulates HTT mRNA levels. Noticeably, the 
degree of HTT mRNA lowering somewhat differs from 
the reduction of HTT protein levels (Figure 2 versus 
Figure 5). This is likely because the HTT protein level is 
determined by the balance point of protein synthesis and 
degradation, which is influenced by not only HTT mRNA 
levels, but also the dynamics of HTT translation and 
degradation. This will result in a non-linear relationship 
between mRNA and protein levels.
Consistent with the observation that MAPK11 may 
regulate HTT protein levels through regulating HTT 
mRNA levels, the Htt protein degradation rate was not 
increased by knocking down Mapk11 (Figure 5D). In ad-
dition, Mapk11-mediated Htt regulation was not affected 
by inhibitors of proteasome or autophagy (Figure 5E), 
the two major protein degradation machineries. 
There are two major mechanisms through which 
MAPK11 may regulate HTT mRNA levels: transcription 
and mRNA stability. To test the possible regulation of 
HTT transcription by MAPK11, we examined HTT pro-
moter activity using a previously published reporter assay 
for the HTT promoter [48] and utilizing the longest ver-
sion of the described HTT promoter. Mapk11 knockdown 
did not change HTT promoter activity in STHdhQ7/Q111 
cells (Figure 5F), suggesting that the Mapk11-mediated 
effect on HTT mRNA is not mediated by regulation of 
HTT transcription, but probably through HTT mRNA sta-
bility. We therefore measured HTT mRNA degradation 
and discovered that it was significantly accelerated by 
knocking down MAPK11 in both STHdhQ7/Q111 cells and 
patient iPSC-derived HD Q47 neurons (Figure 5G), con-
firming that MAPK11 regulates HTT mRNA stability. 
In contrast, knockdown of Hipk3 did not significantly 
influence Htt mRNA levels (Supplementary information, 
Figure S7A). On the other hand, HIPK3 knockdown 
accelerated HTT protein degradation (Supplementary in-
formation, Figure S7B and S7C). In addition, the HIPK3 
knockdown-induced mHTT reduction was blocked by 
own accumulation and thereby, disease progression.
MAPK11- and HIPK3-mediated effects are dependent on 
their kinase activities
In order to lower mHTT levels and treat HD via 
targeting MAPK11 or HIPK3, we asked whether their 
effects on mHTT levels were dependent on their kinase 
activities, which could be targeted by low-molecular 
weight compounds. MAPK11 belongs to the p38 MAPK 
family, and it is phosphorylated by MAP2K6 to activate 
its kinase activity [25]. In HD cells including both STH-
dhQ7/Q111 and iPSC-derived Q47 neurons, knockdown 
of MAP2K6 by siRNAs (Supplementary information, 
Figure S2C) also reduced mHTT levels, an effect not 
seen in WT cells (Figures 2B and 4A). In addition, the 
MAP2K6-mediated effect on HTT is dependent on 
MAPK11 (Supplementary information, Figure S3A). 
Thus, MAPK11’s effect on HTT is likely to be dependent 
on its kinase activity, which is activated by MAP2K6. 
Consistent with this idea, we found that dominant neg-
ative MAPK11 (DN-MAPK11) [43] reduced Htt levels 
when over-expressed in HD cells (Figure 4B). Moreover, 
over-expression of MAPK11 but not DN-MAPK11 sig-
nificantly suppressed the Htt lowering effect of Mapk11 
knockdown (Figure 4C), confirming that MAPK11’s 
kinase activity is required for its role in regulating HTT 
levels. We then tested the potential effects of the Mapk11 
inhibitor SB202190 [44] on Htt levels. However, 
SB202190 treatment failed to reduce Htt levels in STH-
dhQ7/Q111 (not shown), possibly because of the off-target 
effects on other kinases. We therefore tested its effect in 
other HD models and discovered that SB202190 treat-
ment was able to reduce Htt levels in a Mapk11-depen-
dent manner in primary striatal neurons cultured from the 
KI HD mice (HdhQ7/Q140) (Figure 4D), further confirming 
the kinase-activity dependence and providing an entry 
point for HD drug discovery.
Similarly, over-expression of mouse Hipk3 cDNA 
increased endogenous Htt levels, while over-expression 
of the kinase-dead Hipk3 cDNAs (K226M and D322N) 
[45, 46] gave a modest reduction in Htt (Figure 4E). 
This suggests that Hipk3-mediated Htt regulation is also 
kinase activity-dependent. Consistently, the HIPK3 ki-
nase inhibitor AST487 [47] effectively lowers mHTT 
levels (Figure 4F and 4G), and this effect is mitigated 
by knocking down HIPK3 (Figure 4F and 4G, right pan-
els), confirming that AST487 reduces mHTT levels via 
inhibiting HIPK3. Finally, AST487 also reduced mHTT 
levels in the HD patient iPSC-derived neurons (Figure 
4H), confirming the effects in a human neuronal model 
expressing a polyQ length that is close to the ones com-
monly found in HD patients. 
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Figure 4 Mapk11 and Hipk3 regulate Htt levels via their kinase activities. (A) Representative western blots and quantifications of 
Htt levels in the HD (STHdhQ7/Q111) cells or WT (STHdhQ7/Q7) cells transfected with the indicated siRNAs. (B) Representative western 
blots and quantifications of Htt levels in the HD (STHdhQ7/Q111) transfected with dominant negative MAPK11 cDNA (DN-MAPK11) 
versus MAPK11 cDNA (MAPK11) plasmids. (C) Representative western blots and quantifications of Htt levels in the HD (STHdhQ7/Q111) 
transfected with indicated siRNAs targeting Mapk11 and cDNA plasmids expressing MAPK11 or DN-MAPK11. (D) In primary cul-
tured striatal neurons from HdhQ7/Q140 mice transfected with the scramble control siRNA or the Mapk11 siRNA (Mapk11_si2), the 
dose-dependent curves of the Htt levels upon treatment of the p38 Mapk inhibitor SB202190 were measured by HTRF using the 
2B7/2166 antibody pair. Data plotted as mean and SEM, n = 6. Curves were fitted by the Sigmoidal dose-dependent curve. (E) 
Representative western blots and quantifications showing that over-expression of the wild-type Hipk3 cDNA (HIPK3) increases 
Htt levels in the STHdhQ7/Q111 cells, while the kinase-dead Hipk3 (K226M and D322N) has no such effects. (F) Left, Representative 
western blots showing that treatment with the Hipk3 inhibitor AST487 reduces Htt levels in STHdhQ7/Q111 cells at 10 µM. Right, in the 
STHdhQ7/Q111 cells transfected with the scramble control siRNA or the Hipk3 siRNA (Hipk3_si1), the dose-dependent curves of the 
Htt levels upon treatment of AST487 were measured by HTRF using the 2B7/2166 antibody pair. Transfection of the Hipk3 siRNA 
abolished the Htt lowering effect of AST487. Data plotted as mean and SEM, n = 10. Curves were fitted by the Sigmoidal dose-de-
pendent curve. (G) Similar to (F), but in immortalized HD patient fibroblasts (Q68). In the HTRF experiments in the right panel, HD 
Q68 fibroblasts were transfected with the scramble control siRNA or the HIPK3 siRNA (HIPK3_si1), and the mHTT levels were 
measured by HTRF using the 2B7/MW1 antibody pair. Transfection of the HIPK3 siRNA abolished the effect of AST487. Data 
plotted as mean and SEM, n = 10. Curves were fitted by the Sigmoidal dose-dependent curve. (H) In the HD patient iPSC-derived 
neurons (Q47), mHTT levels upon treatment of AST487 were measured by HTRF using the 2B7/MW1 antibody pair. Data plotted 
as mean and SEM, n = 12. The statistical analysis was performed by one-way ANOVA and Dunnett’s post hoc tests. **P < 0.01. 
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the autophagy flux inhibitors NH4Cl and bafilomycin A, 
but not by the proteasome inhibitors epoxomycin and 
MG132 (Supplementary information, Figure S7D), sug-
gesting that HIPK3 may regulate mHTT levels via auto-
phagy. To further confirm the involvement of autophagy, 
we knocked down several essential autophagy genes 
(ATG5, ATG12, ATG16L, SQSTM1) and found that the 
HIPK3 knockdown-induced lowering of mHTT was sub-
sequently lessened (Supplementary information, Figure 
S7E). Taken together, this indicates that MAPK11 regu-
lates HTT at the mRNA level, whereas HIPK3 regulates 
mHTT, at least partially, through autophagy-mediated 
mHTT degradation. 
To further investigate the potential effect of HIPK3 on 
autophagy, we tested the effect of HIPK3 knockdown on 
autophagy markers p62 (encoded by SQSTM1), LC3 and 
Beclin1. Autophagosome-bound lipidated LC3-II has 
been widely used as an indicator of autophagosomes [49]. 
Beclin1 is a critical subunit of a class III PI-3 kinase 
(Vps34) complex required for autophagosome biogene-
sis [50]. The p62 protein is a receptor that binds LC3-II 
and ubiquitin, and is degraded when the autophagosome 
fuses with the lysosome [51]. p62 is a preferred marker 
for measuring autophagic flux as its decreased levels cor-
relate with increased flux [49]. HIPK3 knockdown led to 
increased LC3-II and Beclin1 levels and decreased p62 
levels in HD patient fibroblasts (Q68), suggesting an in-
crease of autophagosomes and autophagic flux facilitates 
mHTT degradation (Figure 6A). To further confirm the 
effect of HIPK3 on autophagy, we expressed GFP-LC3B 
and observed an increase in the number of LC3 puncta 
that mark autophagosomes (Figure 6B), suggesting in-
creased autophagy. A similar phenomenon was observed 
in the patient iPSC-derived Q47 neurons (Figure 6C and 
6D), confirming the effect in a human neuronal model 
with a polyQ length that is close to the ones commonly 
found in HD patients. Endogenous LC3 was assessed in 
these neurons by immunostaining using an antibody that 
preferentially detects LC3II [52], because over-expres-
sion of LC3-GFP or other LC3 cDNA led to morpho-
logical changes and cytotoxicity in these neurons (not 
shown). Finally, the effect was also confirmed in vivo in 
heterozygous Hipk3 knockout HD mice (Figure 6E).
As a major substrate of HIPK3, DAXX directly in-
teracts with and is phosphorylated by HIPK3 [46, 53] 
and suppresses autophagy flux [54]. Thus, DAXX may 
Figure 5 Mapk11 regulates HTT mRNA levels via regulation of HTT mRNA stability. (A) RT-qPCR results in STHdh cells 
showing that knockdown of Mapk11 lowers Htt mRNA levels in HD (left) but not wild-type cells (right). The X-axis indicates 
the Mapk11 mRNA expression level, whereas the Y-axis indicates the Htt mRNA level. As for B-D. Each single point exhibits 
the Htt versus Mapk11 mRNA levels of an independently transfected well, and the numbers are indicated (n). All data were 
normalized to the average of scrambled siRNA-transfected control samples. Red, scrambled siRNA-transfected control sam-
ples; Dark, cells transfected with either of the two Mapk11 siRNAs (Mapk11_si1&Mapk11_si2). The correlation coefficient R 
and P values on top of each plot were calculated by Spearman correlation analysis. “***” on the right side of each plot indi-
cates that P < 0.001 calculated by unpaired two-tailed t tests for the Htt mRNA levels in Mapk11 siRNA-transfected sample 
versus the control. (B) Similar to (A), but in HD patient iPSC-derived neurons (Q47). Data plots and statistical analysis were 
performed in the same way as in (A). (C) Similar to (A), but the mRNAs were extracted from in vivo mouse striata (HdhQ7/Q140 
with or without heterozygous knockout of Mapk11, 4-6.5-month-old), and the statistical analyses were performed the same. 
The “n” numbers indicate the number of mice. (D) The non-radioactive pulse-chase experiment showing that knockdown of 
Mapk11 does not influence Htt protein degradation. The siRNAs were transfected in STHdhQ7/Q111 cells. Three independently 
transfected wells for each point were tested. Data plotted as mean and SEM. The statistical analysis was performed by two-
way ANOVA to determine if the transfection influences the protein degradation. “ns” on the right side of the plot indicates no 
statistically significant interaction between siRNA transfection and Htt protein degradation. (E) The Htt lowering by Mapk11 
siRNA (Mapk11_si2) was measured in STHdh cells by 2B7/2166 HTRF. The proteasome inhibitor epoxomycin or the autoph-
agy inhibitor bafilomycin A (BafA) did not reduce the lowering effect given by Mapk11 knockdown. Bars represent mean and 
SEM, and the numbers indicate the number of independently transfected wells. The statistical analysis was performed by 
one-way ANOVA and Dunnett’s post hoc tests. **P < 0.01. (F) The Htt promoter activity was measured in STHdhQ7/Q111 by the 
luciferase reporter assay (see Materials and Methods). Knockdown of Mapk11 did not significantly influence the Htt promoter 
activity. Blue lines represent mean and SEM, and 10 independently transfected wells were tested for each condition. The sta-
tistical analysis was performed by unpaired two-tailed t tests. (G) Htt mRNA stability measurements in STHdhQ7/Q111 cells (left) 
and HD patient iPSC-derived neurons Q47 (right). The cells were transfected with indicated siRNAs for 36 h and then treated 
with actinomycin D to stop new mRNA synthesis. The Htt/HTT mRNA level was then measured at different time points using 
RT-qPCR, normalized to Hprt/HPRT mRNA levels and plotted as percentage of the initial time point. For HD patient iPSC-de-
rived neurons, β-actin and 18S mRNA were used as controls, which were not influenced by MAPK11 knockdown. Since their 
degradation is close to HPRT and their levels were normalized to HPRT at each time point, the normalized levels were rela-
tively flat across time points. Data were plotted as mean and SEM. The statistical analysis was performed by two-way ANOVA 
to determine if the transfection influences the mRNA degradation. ***P < 0.0001 for the effect of MAPK11 siRNA on Htt mRNA 
degradation.
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participate in the HIPK3-mediated regulation of mHTT 
levels via autophagy. Knocking down DAXX (Figure 7A) 
blunts the effect of HIPK3 on regulation of mHTT levels 
in patient fibroblasts and patient iPSC-derived neurons 
(Figure 7A and 7B), suggesting the involvement of 
DAXX in HIPK3-mediated mHTT regulation. 
We then further tested if HIPK3 regulates autophagy 
through DAXX as predicted. In patient iPSC-derived 
neurons (Q47), the knockdown of DAXX mitigated the 
effect of HIPK3 knockdown on LC3 puncta and LC3II/
p62 levels (Figure 7C and 7D). This confirms that HIPK3 
regulates autophagy via DAXX. Finally, lowering HIPK3 
significantly reduced the level of DAXX protein (Fig-
ure 7E), possibly due to a reduction of phosphorylated 
DAXX protein. Taken together, this indicates that HIPK3 
regulates mHTT levels via the autophagy suppressor 
DAXX.
In summary, MAPK11 and HIPK3 regulate mHTT 
levels through a potential positive feedback loop via dis-
tinct mechanisms, as illustrated in the model in Figure 
7F.
Lowering MAPK11 rescues HD-relevant phenotypes in 
an HD KI mouse model
In order to validate the therapeutic significance of the 
discovered modifiers of mHTT levels, it is critical to test 
whether these targets influence HD-relevant phenotypes. 
Hipk3 knockout may cause metabolic defects [32], while 
the Mapk11 knockout does not seem to have obvious 
phenotypes based on previous reports [33]. While the 
previously reported models were generated by different 
approaches than ours, all available information suggests 
that targeting Mapk11 is probably safer. Thus, we priori-
tized Mapk11 for testing the potential rescue of HD-rele-
vant phenotypes.
At the cellular level, it has been reported that mHTT 
toxicity induces caspase-3 activation under the BD-
NF-deprived culture condition in HD patient iPSC-de-
rived neurons. Thus caspase-3 activation could be used 
as a readout for mHTT-mediated toxicity [55]. We found 
that MAPK11 knockdown significantly lowered the 
mHTT-dependent caspase-3 activation under this con-
dition, suggesting that lowering MAPK11 ameliorates 
mHTT toxicity in HD patient iPSC-derived neurons (Fig-
ure 8A). 
mHTT forms insoluble aggregates in the striata of 
aged HD mice, and these aggregates can be recognized 
by immunofluorescence (Figure 8B; from 11-month-old 
homozygous HD mice HdhQ140/Q140). Compared to homo-
zygous mice, heterozygous HD mice HdhQ7/Q140 exhibited 
many fewer aggregates, and so we focused on homo-
zygous HD mice to better quantify protein aggregates 
and assess Mapk11’s effect on mHtt levels. Remarkably, 
aggregation levels in these homozygous HD mice were 
reduced to wild-type levels when the mice were also ei-
ther Mapk11+/− or Mapk11−/−  (Figure 8B). This is quite 
striking considering that soluble mHTT was reduced by 
less than 50% in the Mapk11+/− condition (Figure 2D; 
Supplementary information, Figure S8B). Meanwhile, 
since Mapk11+/− resulted in mHtt reduction well before 
the formation of aggregates, it is likely that either the 
Mapk11+/− or Mapk11−/− genotype reduced soluble mHtt 
at early ages and prevented formation of mHtt aggregates 
(Figure 8B). This is consistent with previous studies, 
which showed a drastic reduction of mHtt aggregates by 
short-term Htt-targeting using siRNA or ASO treatment 
[8, 9].
We further investigated whether the heterozygous or 
homozygous knockout of Mapk11 also rescues HD-rel-
evant behavioral phenotypes in mice. We explored a 
number of behavioral assays including the rotarod test, 
gripping force measurement, the open-field test, activity 
measurement, the water maze test and the nest building 
test in both HD and WT mice. Consistent with other re-
ports [34], we observed several motor function-related 
phenotypes in this model. At the age of 7.5 months, the 
Figure 6 Hipk3 regulates autophagy flux. (A) Representative western blots and quantification of human patient fibroblasts 
(Q68) transfected with HIPK3 siRNAs versus scrambled control siRNA. LC3B-II and Beclin1 levels were increased whereas 
the p62 levels were decreased. The statistical analysis was performed by one-way ANOVA and Dunnett’s post hoc tests. *P < 
0.05. (B) Representative images and quantification of microscopy experiments showing that the number of GFP-LC3 puncta 
was increased by knocking down HIPK3 in patient fibroblasts (Q68) cells transfected with the GFP-LC3 plasmid. Scale bar, 
20 µm. The statistical analysis was performed by one-way ANOVA and Dunnett’s post hoc tests. ***P < 0.001. (C) Similar to 
(A) but from patient iPSC-derived neurons (Q47). The statistical analysis was performed by one-way ANOVA and Dunnett’s 
post hoc tests. *P < 0.05; **P < 0.01. (D) Representative images and quantification of endogenous LC3II puncta in patient 
iPSC-derived neurons (Q47) by immunostaining with the LC3II antibody. Over-expression of LC3 led to toxicity in these cells 
and changed their morphology, and thus endogenous LC3II puncta were examined. Scale bar, 20 µm. The statistical analysis 
was performed by two-way unpaired t tests. ***P < 0.001. (E) Representative western blots and quantification of mouse stria-
ta tissue lysate samples. The genotypes have been indicated. Each point represents a single mouse. Note that the samples 
were from the same mice used in Figure 2D. For all bar plots, data represent mean and SEM, and the numbers indicate bio-
logical replicates for western blots, or the number of cells in imaging analysis. Images were analyzed blindly by ImageJ.
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Figure 7 Hipk3 regulates mHtt levels via DAXX. (A) Left, RT-qPCR and western blots confirming the knockdown of DAXX in HD 
patient fibroblasts (Q68) by its siRNA. Right, mHTT levels in HD patient fibroblasts (Q68) measured by HTRF using the antibody 
pair 2B7/MW1, after transfection of the indicated siRNAs. Transfection of the DAXX siRNA blocked the effect of knocking down 
HIPK3. (B) mHTT levels in HD patient (Q47) primary fibroblasts (left) or HD patient iPSC-derived neurons (right) measured by 
HTRF using the antibody pair 2B7/MW1, after transfection of the indicated siRNAs. Transfection of the DAXX siRNA blocked the 
effect of knocking down HIPK3. (C) Representative images and quantification of endogenous LC3II puncta in patient iPSC-de-
rived neurons (Q47) transfected with the indicated siRNAs. Scale bar, 20 µm. The quantification of the puncta was performed 
blindly, the boxed regions have been magnified and exhibited at the lower right corner for better view of the puncta, but the 
counting was not limited to the boxed regions. The statistical analysis was performed by two-way unpaired t tests. (D) Repre-
sentative western blots and quantification of p62 and LC3 blots of patient iPSC-derived neurons (Q47) transfected with the indi-
cated siRNAs. (E) Representative western blots and quantification of DAXX in patient iPSC-derived neurons (Q47) transfected 
with the indicated siRNAs. (F) A model illustrating the positive feedback loop mediating MAPK11 and HIPK3’s effect on mHTT 
levels. For all bar plots, data represent mean and SEM. The statistical analysis was performed by two-way unpaired t tests for A 
to D, and by one-way ANOVA followed by Dunnett’s post hoc tests for E and F. *P < 0.05; **P < 0.01; ***P < 0.001; ns, P > 0.05.
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Figure 8 Lowering Mapk11 rescues HD-relevant phenotypes in iPSC-derived HD neurons and HD knockin mouse model. 
(A) Left panels, representative phase-contrast (for cell confluence and morphology) and green fluorescence images (for 
caspase-3 activity using the caspase-3 detection dye) of the wild-type (WT, Q19) or the Huntington’s disease (HD, Q47) 
iPSC-derived neurons transfected with the indicated siRNAs under BDNF deprived conditions for 48 h. Scale bar, 100 µm; 
Right panel, quantification of the number of caspase-3 signals (green particle counts × size × mean intensity) per field by 
IncuCyte software. The numbers on top indicate the number of independently transfected wells. 4 fields of each well were 
imaged for quantification by IncuCyte inside the cell culture incubator. All the signals were normalized to the average of the 
HD cells. Bars represent mean and SEM. The statistical analysis was performed by one-way ANOVA and Dunnett’s post hoc 
tests. (B) Left panels, representative images of the Htt aggregates (by the antibody S830) alone or merged with DAPI and 
Darpp32. The scatter plot, quantification of the total aggregate signals (aggregate counts × size × mean intensity) per cell 
by particle analysis using ImageJ. Data were from 12 different slices from 3 mice of each genotype. Scale bar, 20 µm. The 
imaging and the analysis were performed blindly before revealing the genotypes. The statistical analysis was performed by 
one-way ANOVA and Dunnett’s post hoc tests. (C) The total number of active behaviors (activities) in 5 min for each mouse 
of the indicated genotypes tested in the pen holder with mashed surface. Unpaired two-tailed t test was performed between 
the HD (HdhQ140/Q140) and WT (HdhQ7/Q7) mice without Mapk11 deletion (Mapk11+/+); one-way ANOVA and Dunnett’s post hoc 
tests were performed within the HD and WT groups. (D) Left, the total distance traveled in 15 min for mice of the indicated 
genotypes tested in the open-field. Right, the open-field was divided into 4 × 4 virtue grids for analysis, and the number of 
times that each mouse crossed the borders of the middle 4 blocks was quantified. The statistical analysis was performed and 
indicated as in (C). (E) Representative footprints of mice of indicated genotypes. (F) The plot of the top principle component 
(Coupling PC1) of the gait coupling parameters (Supplementary information, Table S1). The statistical analysis was performed 
and indicated as in (C). (G) Summary of the number of rescued (green) versus exacerbated (orange) parameters by Mapk11 
heterozygous or heterozygous knockout. The category was judged by the direction of changes. Heterozygous or homozygous 
knockout of MAPK11 in HD mice led to predominantly more rescues (green) than exacerbations (orange), suggesting rescue 
effects. See Supplementary information, Table S2 for the selected parameters. For all plots, error bars represent mean and 
SEM. The numbers on top of each plot indicate the number of mice. For all the behavioral experiments and aggregation im-
munofluorescence, mice were tested blindly and their genotypes were revealed after data recording and analysis. Immunoflu-
orescence data were obtained from 11 month old mice and behavioral data were obtained from 7.5 month old mice.
homozygous HD (HdhQ140/Q140) mice showed less activity 
(measured by the frequency of active behaviors includ-
ing rearing and climbing) in a pen holder with mashed 
surface (Figure 8C, comparison between the first group 
of each plot). They also exhibited mobility defects in the 
open-field test (Figure 8D, comparison between the first 
group of each plot). However, we failed to detect reliable 
behavioral phenotypes in the heterozygous HD mice 
(HdhQ7/Q140, Supplementary information, Figure S8A) and 
thus performed further testing in the homozygous HD 
mice. By crossing the Mapk11 knockouts to the HD mice 
for several generations, we obtained both Mapk11 hetero-
zygous (Mapk11+/−) and homozygous (Mapk11−/−) knock-
outs and related controls (Mapk11+/+) in both the HD 
(HdhQ140/Q140) and WT (HdhQ7/Q7) backgrounds. The sol-
uble mHtt level was significantly lowered by Mapk11+/− 
in striata from these mice (Supplementary information, 
Figure S8B), similar to heterozygous HD mice (Figure 
2D). Both Mapk11+/− and Mapk11−/− genotypes showed 
significant (P < 0.05) or marginal (P = 0.1) rescue of the 
behavioral defects of the HD mice in activity (Figure 
8C) and open-field tests (Figure 8D). These data confirm 
the protective effect of lowering Mapk11 on HD pheno-
types. Of note, although Mapk11+/− and Mapk11−/− caused 
a mild reduction of the activity frequency in the WT 
background, such an effect was reversed in the HD back-
ground (Figure 8C). In the open-field tests, Mapk11+/− 
and Mapk11−/− did not have positive effects in the WT 
background, but they did show a rescue effect in the HD 
background (Figure 8D). The results confirm that the ef-
fects of Mapk11+/− and Mapk11−/− on motor functions are 
HD-specific since no positive effects were observed in 
the WT background.
HD patients have gait phenotypes and show impaired 
coupling [56]. We thus further tested the potential gait 
phenotype of these HD mice by the gait analysis system, 
which records the gait of mice passing through a scoring 
lane (Supplementary information, Movies S1-S2). The 
HD mice showed some gait abnormalities with more 
irregular steps and more overlaps of footprints; these 
abnormalities seemed to be rescued in the Mapk11+/− and 
Mapk11−/− backgrounds (Figure 8E; Supplementary infor-
mation, Movies S1-S2). Of the 214 parameters quantified 
by the gait analysis equipment, 36 are coupling-related 
parameters. In order to capture the major components of 
the gait coupling phenotype, we have applied principle 
component analysis [57] to all these 36 coupling-related 
parameters and revealed the top principle component that 
depicts the defects in the HD mice (Figure 8F and Sup-
plementary information, Table S1). Based on the PCA 
analysis, the gait defects were markedly improved in 
Mapk11+/− and Mapk11−/− HD mice (Figure 8F). 
1458
MAPK11 and HIPK3 regulate mutant Huntingtin
SPRINGER NATURE | Cell Research | Vol 27 No 12 | December 2017
To further confirm Mapk11’s effect, we analyzed all 
the 214 single parameters without PCA transformation. 
We identified 6 out of the 214 parameters that showed 
a significant (P < 0.05) difference between HD and WT 
animals (Supplementary information, Table S2, yellow 
blocks). None of these six parameters are standard pa-
rameters in describing gait defects and they are unlikely 
to capture the major differences between HD and WT 
sufficiently. Given that there are so many parameters 
analyzed, these six parameters may have just passed the 
P < 0.05 threshold by chance. To capture the gait defects 
more accurately, we selected all the 26 parameters that 
showed at least a 10% difference with a relatively small 
P value (P < 0.2, by unpaired two-tailed t tests) between 
the HD and WT groups. We then determined whether the 
phenotype captured by a single parameter was rescued 
or exacerbated by comparing the averages of Mapk11+/− 
or Mapk11−/− with Mapk11+/+ mice in the same Htt back-
ground; the judgment was solely based on the direction 
of the changes (Supplementary information, Table S2). 
If the parameters were not influenced, random noise 
should result in equal probability of rescue versus exac-
erbation. In the HD mice (Supplementary information, 
Table S2, right parts), Mapk11+/− and Mapk11−/− showed 
overwhelmingly more rescues (green) than exacerbations 
(orange), an outcome highly unlikely to have resulted 
from random noise (Mapk11+/−: 21 rescues versus 5 ex-
acerbations, P = 0.0009; Mapk11−/−: 22 rescues versus 4 
exacerbations, P = 0.00009; Mapk11+/−& Mapk11−/− to-
gether: 43 rescues versus 9 exacerbations, P = 5E−7). In 
the WT mice, Mapk11+/− and Mapk11−/− did not have such 
effects (Supplementary information, Table S2, left parts). 
These distributions were summarized in a bar plot (Fig-
ure 8G) and strongly suggested that lowering Mapk11 
significantly rescued mHTT-induced gait phenotypes. 
Finally, while behavior phenotypes in the heterozygous 
HD mice (HdhQ7/Q140) were too weak to be assayed (Sup-
plementary information, Figure S8A), they exhibited 
significantly lower levels of the medium spiny neuron 
marker Darpp32 compared to the WT (Supplementary 
information, Figure S8C). Moreover, this phenotype 
was also rescued by heterozygous knockout of Mapk11 
(HdhQ7/Q140, Mapk11+/−) (Supplementary information, Fig-
ure S8C), suggesting that the rescue effect of lowering 
Mapk11 is also present in heterozygous HD mice.
Collectively, our data provide encouraging in vivo 
evidence to establish Mapk11 as a potential therapeutic 
target for HD drug discovery. While we cannot entirely 
exclude the involvement of other mechanisms in the phe-
notypic rescue, lowering mHtt is most likely the major 
mechanism that rescues HD phenotypes, because lower-
ing Mapk11 reduces mHtt in vivo and reduction of mHtt 
by various approaches has been shown to rescue HD 
phenotypes.
Discussion
Screening for HTT protein modifiers
In summary, using an unbiased genetic screen and 
validating the output, we have identified MAPK11 and 
HIPK3 as robust modulators of HTT levels both in cells 
and in vivo (Figure 2). This regulation is dependent on 
their kinase activity, providing promising opportunities 
for drug development (Figure 4). Finally, heterozygous 
or homozygous deletion of Mapk11 lowers mHTT ag-
gregates in HD striata and rescues the behavioral pheno-
types of the HD mice in vivo, confirming the therapeutic 
potential of reducing the activity of this protein kinase.
Disease progression-modifying treatments are highly 
desired and yet unavailable for neurodegenerative dis-
orders. Lowering disease protein levels is a promising 
strategy to achieve this goal. For HD, previous screening 
efforts focused on protein aggregation, cleavage or toxic-
ity [58-61]. Our present study focuses on decreasing sol-
uble mHTT levels for two reasons: first, soluble mHTT 
has been shown to be closely related with toxicity [11-13]; 
second, as the mechanism underlying mHTT toxicity is 
unclear, we chose to focus on the presence of soluble 
mHTT as an earlier event in disease pathogenesis. This 
approach would ensure that changes achieved in protein 
level should cascade through downstream steps and im-
pact disease-relevant phenotypes, including aggregation 
(Figure 8B). 
In our previous screening effort using Drosophila S2R 
cells, we only obtained hits that upregulate mHTT when 
knocked down [30]. This is likely because the primary 
screen was performed in cells over-expressing exogenous 
mHTT fragments, and the screening system may elevate 
pathways that clear the over-expressed mHTT fragments 
and thus could be biased towards enhancer hits in a 
knockdown screen. Here we optimized the screen in hu-
man patient fibroblasts expressing the endogenous full-
length human mHTT protein and focusing upon targets 
that may reduce mHTT when knocked down.
Other than MAPK11 and HIPK3, we identified a num-
ber of other targets (including the gene for MAPK11’s 
upstream regulator MAP2K6) that reduced mHTT and 
rescued hESC-derived Q73 neurons in our knockdown 
screen (Figure 1). The negative correlation between 
mHTT-exon1 protein level and neuronal survival strongly 
suggests that these targets reduce mHTT toxicity through 
lowering its level (Figure 1E), although further validation 
with more replicates and in more HD models is definitely 
needed. MAPK11 and HIPK3, as well as the other newly 
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identified targets have not previously been reported to 
have physical interactions with HTT. Thus, they probably 
regulate mHTT through indirect mechanisms rather than 
through a direct interaction with mHTT. Noticeably, be-
sides the identified kinases, the targets USP39, RNF145 
and PRPF19 are all related with ubiquitination process-
es, whereas MMP25, NPEPL1 and ECE1 are proteases/
peptidases. This suggest that ubiquitination and protein 
cleavage likely play important roles in mHTT modula-
tion. Like any other high-throughput screen, our screen 
may identify false-targets due to the limitations of cellu-
lar models, HTT detection and insufficient knockdown. 
The siRNA library used for our screens were ordered 
from Qiagen Inc., and most of them have been validated 
based on the manufacturer’s information. Consistently, 
most of the siRNAs knocked down their targets more 
than 70% based on our qPCR validation of transcript 
levels in our present and previous studies. In addition, 
we tested four siRNAs targeting each gene and two pos-
itive siRNAs were used as the hit selection criteria. This 
further decreases the false-negative rate, although we can 
never completely exclude them. 
Reducing wtHTT
Lowering Mapk11 or Hipk3 reduces both mHtt and 
wtHtt in HD cells (Figure 2). This raises an important 
concern over the tolerance of losing wtHTT, which is 
essential for embryonic development [15, 16, 62]. Con-
sistently, it has been reported that compound heterozy-
gous variants in HTT are found in association with an 
autosomal recessive neurodevelopmental disorder [63]. 
Presence of a single-nucleotide polymorphism on the 
WT HTT allele that represses HTT transcription is asso-
ciated with an earlier age of onset in HD patients in an 
extreme case-based cohort [17]. A very recent study also 
suggested that very low levels of wtHtt in mice during 
embryonic and postnatal development may lead to HD-
like phenotypes later [64]. These studies suggest that loss 
of wtHTT to a certain extent may be harmful and may 
contribute to HD as well. On the other hand, lowering 
wtHTT levels up to 60%-70% has been shown to be safe 
in a primate model [65] and ablation of wtHTT in adult 
mice at > 4 months of age does not lead to neurodegen-
eration or other defects in mouse models [66], suggest-
ing that lowering wtHTT in old adults is well tolerated. 
Consistent with this, HTT-lowering by RNAi or ASOs 
targeting both mHTT and wtHTT showed significant 
benefits in HD models [7-9, 67, 68], confirming lowering 
both mHTT and wtHTT as a potential strategy for HD 
treatment. Encouragingly, the IONIS HTT-Rx clinical 
trial has been launched, using a non-allele specific ASO, 
HTTRx, for HD treatment (https://www.clinicaltrials.
gov/ct2/show/NCT02519036). Another appealing strat-
egy is to use allele-specific HTT ASOs to selectively 
lower mHTT [36, 69-71], although whether HD-relevant 
phenotypes in vivo could be rescued by the allele-specific 
strategy needs to be further addressed. Taken together, 
while lowering both mHTT and wtHTT to a certain ex-
tent may be beneficial, precautions need to be taken due 
to the potential harmful effects of reducing wtHTT to an 
intolerable extent. 
In our study, lowering Mapk11 or Hipk3 reduces 
wtHtt by the extent of < 50% in vivo (Supplementary 
information, Figure S6B), and the reduction of wtHTT 
level appears within its tolerable range according to 
previous studies. Indeed, lowering Mapk11 by genetic 
silencing led to rescue rather than exacerbation of pheno-
types in HD mice and cells (Figure 8).
We believe that mHtt lowering per se is likely to 
be the major mechanism that mediates the effect of 
Mapk11 on HD-relevant phenotypes, given the com-
pelling evidence showing that reducing mHtt by many 
different approaches including directly knocking down 
Htt can rescue HD-relevant phenotypes [5-8, 68]. This 
is because the potential diverse secondary effects from 
these approaches are unlikely to lead to rescuing effects 
through a common mechanism. Importantly, although 
lowering Mapk11 has no positive effects in WT mice 
in the behavioral assays, it rescues HD mice (Figure 8), 
suggesting that the effect is likely mediated through the 
lowering of mHtt. However, it is impossible to entirely 
exclude potential secondary effects that may have also 
been involved. Nevertheless, identification of Mapk11 as 
a potential druggable target to lower mHtt and associated 
toxicity warrants its further study for HD therapy.
HD mouse models
Currently over a dozen HD mouse models have been 
established for various studies, including N-terminal 
HTT fragment models that include N171-82Q and R6 
mice [72, 73]; full-length transgenic models such as 
BACHD or YAC128 [74, 75]; or KI models such as 
Q140 and zQ175 [34, 76]. Each model has its own char-
acteristics and advantages depending on the experimental 
approach to be taken. In this study, we chose to use a KI 
model, which expresses a human-mouse chimeric mHtt 
protein from the original locus of Htt at endogenous lev-
els [34] and this faithfully depicts HD genetics. Similar 
to human patients, the polyQ length in the KI mouse 
models correlates well with the degree and the age of 
onset of HD-relevant transcriptional dysregulation and 
behavioral deficits [77, 78], thus confirming KI mice as a 
reliable HD model. Among the commonly used KI mod-
els, the zQ175 model expresses the longest polyQ tract 
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and has the strongest phenotypes [76], but this model 
shows significant weight loss and the age of onset of be-
havioral deficits is around 4.5 months (20-30 years in hu-
man age), much earlier than the age of onset in most HD 
patients (40-50 years old). The KI model that we used in 
this study, HdhQ140 [34], has relatively mild behavioral 
phenotypes which are only observable in homozygous 
mice at least under our experimental conditions (Figure 
8). On the other hand, while all the other models men-
tioned above display weight changes, the HdhQ140 mod-
el does [34], thus minimizing potential artifacts from this 
aspect. In addition, the age of onset of behavioral deficits 
(~7 months) in this model is analogous to that of HD pa-
tients. Particularly, our study has revealed that Mapk11 
regulates endogenous Htt mRNA levels. Given that KI 
mice express mHtt from the endogenous mouse Htt pro-
moter [34], we reason that KI models are well suited for 
our study to examine the effects of Mapk11. Thus, we 
utilized HdhQ140 for our first in vivo validation.
MAPK and polyQ proteins
MAPK11 regulates HTT levels by regulating stability 
of its mRNA while HIPK3 regulates mHTT via autopha-
gy. As a novel modulator of autophagy, HIPK3 may not 
only be able to regulate mHTT, but also other disease 
proteins degraded by autophagy. Interestingly, wtHTT 
could also be regulated by HIPK3 in the presence of 
mHTT (Figures 2 and 3), suggesting that autophagy 
may partially mediate wtHTT degradation as well. This 
may not be surprising given that wtHTT protein partici-
pates in the autophagy process [79, 80]. While we have 
revealed a mechanistic sketch of MAPK11-mediated 
and HIPK3-mediated HTT regulation, many mechanis-
tic details remain to be identified. We discovered that 
MAPK11 mainly regulates HTT mRNA stability (Figure 
5), but the downstream mechanism of its action is still 
unclear. Since MAPK family members are known to 
regulate RNA binding proteins and miRNAs [81, 82], we 
speculate that MAPK11 regulates HTT mRNA via certain 
RNA binding protein(s) and/or miRNA(s), which will 
need further study to confirm. Similarly, the mechanistic 
details need to be determined of how HIPK3 regulates 
autophagy through DAXX.
MAPKs can have critical and systematic involvement 
in regulating mHTT/polyQ proteins. Another hit from 
our screen, MAP2K6, is known to be a stress sensor up-
stream of MAPK11. HIPK3 has been shown to be elevat-
ed by JNKs [26], which are also members of the MAPK 
family that mediate the stress response downstream of 
polyQ expansion proteins [83]. In addition, other mem-
bers of the MAPK family have been shown to elevate the 
levels of mutant ATXN1 [14], another disease-causing 
polyQ expansion protein. The homolog of MAP2K6 in 
Caenorhabditis elegans, sek-1, has been shown to in-
crease the expression of the polyQ expansion protein, 
pqn41-c, which leads to linker cell death during devel-
opment [84]. Collectively, the MAPKs appear to play 
vital roles in regulating polyQ proteins that can lead to 
cell death during both disease and development, and they 
may provide a critical link between stress and cell death 
by regulating the polyQ-expansion proteins. 
Materials and Methods
Plasmid constructs
The human HTT-exon1 constructs (Q72 and Q25) were syn-
thesized by Thermo Fisher Scientific and subcloned into the 
pcDNA/DEST40 vector (Thermo Fisher Scientific, #12274-
015). The mouse full-length Hipk3 cDNA was codon-optimized 
and synthesized by Thermo Fisher Scientific and subcloned into 
the pTT5SH8Q2 vector (NRC Biotechnology) with N-termi-
nal GFP tag. The human or rat Hipk3 cDNA failed to express 
efficiently in STHdh cells. The Q72-GFP construct (expressing 
Methionine-Q72-GFP) was cloned by PCR amplification from 
the HTT-exon1 constructs, and ligation to the pcDNA-GFP plas-
mid. The QuikChange Site-Directed Mutagenesis Kit (Agilent 
Technologies) was used to generate the point mutation constructs: 
kinase-dead mouse Hipk3 (K226M and D322N), DN-MAPK11 
(TGY (180-182) to AGF). The MAPK11 (#20355) and GFP-LC3B 
(#24987) construct was obtained from Addgene.
Cell culture and cell line generation
STHdh (CH00097 – Q7/Q7 and CH00096 – Q111/Q7) and 
human fibroblasts (GM03868 – Q45; GM21757 – Q68) were ob-
tained from Coriell Cell Repositories. The Q47 fibroblasts were 
obtained from a Mongolian HD patient, and the study was ap-
proved by the ethic community of IBS at Fudan University (No.28). 
Verbal and written consent was obtained from patients. STHdh 
cells were cultured in DMEM (Thermo Fisher Scientific, #11965) 
with 10% FBS (Thermo Fisher Scientific, #10082). Immortalized 
human patient fibroblasts were generated by SV40 large T-anti-
gen and cultured in DMEM with 15% FBS. Primary fibroblasts 
were cultured under the same condition. Human ESC-derived 
neurons stably expressing HTT-exon1 fragments were generated 
and authenticated as previously reported [13], and the generation 
and authentication of HD iPSC-derived neurons were described 
previously [29]. All the mammalian cell lines were maintained at 
37 °C incubator with 5% CO2, except STHdh cells, which were 
maintained at 33 °C with 5% CO2. The cells were tested for my-
coplasma contamination every month. Primary mouse neurons 
from striata acutely dissected from P0 pups and tissue was digest-
ed with Trypsin (Sigma, #T1005, 2 mg/ml) and DNaseI (Roche, 
#10104159001, 1 mg/ml) in DMEM for 30 min with occasional 
mixing. The digestion was then stopped by 10% serum, and the 
tissue was then triturated and plated in the Neurobasal A medium 
(Thermo Fisher Scientific, #21103049) supplemented with 1× B27 
(Thermo Fisher Scientific, #17504044), 1× N2 (Thermo Fisher 
Scientific, #17502048), 0.5× Antibiotic-Antimycotic (Thermo 
Fisher Scientific, #15240062) and 1× Glutamax (Thermo Fisher 
Scientific, #35050061)
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Neuronal loss and apoptosis measurements
The secondary screen for neuronal loss of hESC-derived HD 
neurons was performed similarly to a previously study [13]. Basi-
cally, the neurons were moved from protective culture condition 
to standard culture condition and displayed mHTT-dependent neu-
ronal shrinkage and death, which could be quantitated by conflu-
ence measurement using incuCyte (Essen Biosciences) [13]. For 
measurements of caspase-3 activity of the iPSC-derived neurons, 
the NucView 488 caspase-3 dye (Biotium, #30029) was used for 
the caspase 3 activity detection as an indicator of apoptosis. The 
images of the caspase-3 dye treated cells were taken by IncuCyte 
automatically. The phase-contrast images were then taken by the 
IncuCyte equipment (Essen BioScience) and analyzed for conflu-
ence by the IncuCyte software. 
Protein extraction and western blots
Cell pellets were collected and lysed on ice for 30 min in 1× 
PBS+1% Triton X-100+1× Complete protease inhibitor (Roche), 
sonicated for 10 s, and centrifuged at > 20 000× g at 4 oC for 10 
min. The supernatants were then loaded and transferred onto nitro-
cellulose membranes for western blots. For mouse brain tissues, 
the striata and cortices were dissected on ice and ground with a tis-
sue grinder for 5 min at 60 Hz and lysed on ice for 60 min in brain 
lysis buffer (50 mM Tris, 250 mM NaCl, 5 mM EDTA, 1% Triton 
X-100 pH=7.4) + 1× Complete protease inhibitor (Roche). The 
samples were then spun at > 20 000× g at 4 oC for 15 min. The sus-
pensions were then collected for western blots. The anti-HTT anti-
bodies 2B7 [18], ab1 [85] and MW1 [86] have been described pre-
viously. The antibody S830 for immunostaining of Htt aggregates 
is a kind gift from Dr Gillian Bates. Commercially purchased anti-
bodies include anti-HTT antibodies 2166 (Millipore, #MAB2166, 
RRID:AB_2123255), 3B5H10 (Sigma, #P1874), anti-β-tubulin 
(Abcam, #ab6046, RRID:AB_2210370), anti-Ataxin3 (Milli-
pore, #MAB5360), anti-Mapk11 (Thermofisher Scientific, #33-
8700), anti-Tuj1 (Covance, #MMS-435P, RRID:AB_2313773), 
anti-Darpp32 (Abcam, #ab40801, RRID:AB_731843), anti-P62 
(Abcam, #ab56416, RRID:AB_945626), anti-DAXX (Protein-
tech, #20489-1-AP, RRID:AB_10693620), anti-LC3B (Pro-
teintech, #18725-1-AP), anti-HIPK3 (Santa cruz, #sc-66920, 
RRID:AB_2117734) ), anti-β-actin (Abcam, #ab6276), anti-Cal-
nexin (Enzo, #ADI-SPA-860-F), anti-Gapdh (Santa cruz, #sc-
25778), anti-α-tubulin (Proteintech, #11224-1-AP), anti-MAP2 
(Santa cruz, #sc-20172), anti-phospho-ATF2 (Cell Signaling Tech-
nology, #9225, RRID:AB_2060933), anti-ATF2 (Cell Signaling 
Technology, #9226, RRID:AB_2060930), anti-Phospho-p38 (Cell 
Signaling Technology, #4511, RRID:AB_2139682), anti-Beclin1 
(Thermofisher, #PA1-46464) and anti-LC3 antibody that preferen-
tially detects LC3II (Thermofisher, #70012) [52]. The specificity 
of all antibodies has been validated by previous reports or our 
knockdown or knockout experiments. 
Homogeneous time-resolved fluorescence assay
The HTRF assays were performed similarly to those previously 
described [30]. Basically, the cells were lysed in the lysis buffer 
(1× PBS with 0.4% Triton X-100 and 1× protease inhibitor final) 
and the target detected with indicated antibody pairs. The princi-
ples are explained in Supplementary information, Figure S1. Note 
that the 2B7/MW1 antibody pair is needed to test mHTT in human 
cells, while this antibody pair does not work properly in mouse 
STHdh cells. Another antibody pair 2B7/2166 was used to mea-
sure Htt levels (wtHtt and mHtt) in mouse STHdh cells [28]. This 
antibody pair could also be used to detect wtHTT proteins in the 
WT cells or HTT proteins including both mHTT and wtHTT in the 
HD cells [21]. For all samples, the total protein concentration (by 
BCA, Pierce, #23225) and/or the total DNA content (by Picogreen, 
#P7589) were measured to correct the loadings. Different protein 
concentrations or cell numbers per well were tested to ensure that 
the signals were in the linear range. Background corrections were 
performed by subtracting the background signals from blank sam-
ples.
cDNA and siRNA transfection
The siRNAs were reversely transfected into the STHdh cells 
with lipofectamine 2000 (Life Technologies, #11668) and into the 
iPSC-derived neurons with lipofectamine RNAiMAX (Life Tech-
nologies, #13778) whereas cDNAs were transfected with lipofect-
amine 3000 (Life Technologies, # L3000). All transfections were 
performed according to the manufacturer’s protocol. Cells were 
collected 3 days after siRNA transfection or 2 days after cDNA 
transfection for western blot, HTRF or Immunofluorescence. All 
siRNAs have been validated by qPCR and/or western blots for tar-
get knockdown. For the siRNA target sequences, see Supplemen-
tary information, Data S1.
Mouse models
The generation and characterization of the Hdh140Q KI mice 
have been previously described [34]. Mice were provided by Dr. 
Marian DiFiglia at Massachusetts’s General Hospital, USA. The 
mice were then bred at the mouse facility at Fudan University. 
Mapk11 and Hipk3 knockouts were generated by Cyagen Biosci-
ences Inc. using TALEN technology. The knockout mice were 
produced by microinjecting TALEN mRNAs into fertilized eggs 
from the C57BL/6 strain. The knockout alleles were validated by 
sequencing for an early frameshift of the target genes as well as 
western blots (Supplementary information, Figure S5). The mice 
were back-crossed to the C57BL/6 WT background for five gen-
erations before crossing to the HD mice (with the same genetic 
background) or performing other experiments. Mice were group-
housed (up to five adult mice per cage) in individually vented 
cages with a 12 h light/dark cycle. The mouse experiments were 
carried out following the general guidelines published by the As-
sociation for Assessment and Accreditation of Laboratory Animal 
Care. The Animal Care and Use Committee of the School of Med-
icine at Fudan University approved the protocol used in animal ex-
periments (Approval #20140904). For protein extraction from the 
mouse brain, the brains were collected and the striata and cortices 
were acutely dissected.
RT-qPCR
mRNA levels were determined by qPCR. RNA from siR-
NA-transfected or compound-treated cells was extracted using 
RNAprep Pure Cell/Bacteria Kit (Tiangen, #DP430). DNase I was 
added to break down the genomic DNA. Random-primed cDNA 
was obtained by reverse transcription using the FastQuant RT 
Kit (Tiangen, #KR106). qPCR was then performed using SYBR 
Green Realtime PCR Master Mix (Toyobo, #QPK-201). All the 
primers were tested with standard curve, amplification efficiency 
was between 95% and 105%, and the R2 for linear relationship is 
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> 0.999. No reverse-transcriptase controls were used to ensure the 
specificity of the signals. 
mRNA stability measurements were similar as previously de-
scribed [87]. The cultured cells were treated with transcriptional 
inhibitor actinomycin D (5 µg/ml, Sigma, #A9315) and the cells 
were collected at indicated time points after treatment for mea-
surement of HTT mRNA levels by RT-qPCR.
For all the qPCR primer sequences see Supplementary informa-
tion, Data S1.
Nonradioactive pulse-chase experiments
The Click-iT AHA (l-azidohomoalaine) kit (Thermo Fisher 
Scientific, #C10102) was used and the assay was similar to that 
previously described [30, 88]. Briefly, cells were starved with 
methionine-free media for 1 h prior to adding Click-iT AHA for 
12 h (pulse, 50 μM). The cells were then incubated in normal se-
rum-containing media for the indicated periods before harvesting 
(chase) for analysis. The Click-iT AHA labeled proteins were then 
conjugated with biotin by treatment with biotin-DIBO Alkyne 
(Thermo Fisher Scientific, #C10412). The biotin conjugated pro-
teins were then pulled-down using streptavidin beads (Pierce, 
#20349), and the HTT level is determined by HTRF [88]. 
HTT promoter transcription assay
The assay was performed similarly to that previously described 
[48]. Basically, cells were transfected with the reporter plasmid 
expressing firefly luciferase driven by the human HTT promoter 
(pHTT-A) mixed with control plasmid expressing renilla luciferase 
(pRL-TK) using lipofectamine 3000. The pHTT-A and pRL-TK 
plasmids were co-transfected at 10:1 ratio. After 48 h of transfec-
tion, firefly and renilla luciferase activities were measured using 
the dual-glo luciferase reporter assay system (Promega, #E2920). 
The firefly luciferase activity was normalized to the renilla lucifer-
ase activity to reflect the promoter activity.
Compound treatment
For compound treatment, the cells were plated at the same den-
sity as the one for siRNA transfection, and the compounds were 
diluted in OPTI-MEM in 10× concentrations and added 1-2 days 
later. The cells were then collected after 1-2 days for further anal-
ysis. Compounds were obtained as follows: bafilomycin A (Sigma, 
#B1793, 100 nM), epoxomicin (Cayman Chemical, #BU4061T, 
100 nM), MG132 (Sigma, #M7449, 1 µM), ammonium chloride 
(Sigma, #A9434, 10 mM), SB202190 (Sigma, #152121-30-7, at 
indicated concentrations), DPI (Sigma, #D2926, 100 nM, at indi-
cated concentrations) and AST487 (Chemexpress, #HY-15002, at 
indicated concentrations).
Immunofluorescence and immunohistochemistry
For immunofluorescence, cultured cells were fixed in 4% para-
formaldehyde (PFA) after washing with 1× PBS for three times, 
and then permeablizing in 0.5% TritonX-100 for 10 min. The cells 
were then blocked in 4% BSA + 0.1% Triton X-100 in 1× PBS for 
30 min and incubated overnight at 4 °C with primary antibodies, 
and then washed three times with blocking buffer and incubated 
with secondary antibody at room temperature for 1 h. Coverslips 
were then washed three times, stained with 0.5 mg/ml DAPI (Bey-
otime Biotechnology, #C1002) for 5 min at room temperature, and 
then mounted in vectashield mounting medium (Vector, #H-1002). 
For mouse brain slices, mice were killed and then perfused 
with PBS and 4% paraformaldehyde. The brains were then dis-
sected out, and fixed with 4% PFA for 48 h at 4 °C. The brains 
were then incubated in 30% sucrose for 48 h at 4 °C and sec-
tioned at −20 °C into 35 µm thick slices. The immunofluorescence 
experiments were then performed as described above for cells 
except substituting 3% donkey serum for blocking. 
Sample brain slices from human patients were obtained from 
Addenbrookes Hospital (Cambridge, UK) with an appropriate 
ethical approval from Brain UK (14/007). The slices were depar-
affinized with dimethylbenzene, rehydrated with reverse gradient 
ethanol and then boiled in sodium citrate buffer (pH = 6.0) for 
antigen retrieval. Endogenous peroxidase was then quenched with 
3% H2O2. Incubation with primary antibodies (Hipk3: GeneTex, 
#GTX108369 and Mapk11: Thermofisher Scientific #33-8700) 
was at 4 °C overnight after blocking with 4% goat serum. Detec-
tion was with peroxidase streptavidin-biotinylated complex and 
diaminobenzidine (DAB)/H2O2 (Boster, #SA1050). Experiments 
without primary antibodies and knockdown experiments in cells 
were utilized to confirm the specificity of the antibodies. Images 
were taken using Zeiss LSM confocal microscopes.
Mouse behavioral experiments
All the behavioral experiments were performed during the light 
phase and the experimenters were blind to the genotype of each 
mouse. Both males and females were used. All the mice were kept 
in the behavioral test room in dim red light for 1 h before start-
ing the experiments. For activity tests, mice were placed in a pen 
holder with a mashed surface (98 mm height × 91 mm diameter) 
for 5 min. The activity number indicates the total number of active 
behaviors including rearing (lifting two paws, most frequent) and 
climbing (lifting three or more paws onto the wall, rare). For open-
field tests, mice were placed in a 30 × 30 × 40 cm white Plexiglas 
chamber (equipment from Med-Associates) in a behavior room, 
and locomotion was captured by camera on top of the chamber and 
recorded for 15 min. The traveling trace and distance were then 
analyzed using the Med-Associates Activity Monitor program. 
For gait analysis, CatWalk XT was used as a complete system for 
quantitative assessment of the gait of mice. Mice were placed in 
an enclosed walkway on a glass plate and allowed to traverse from 
one side of the walkway to the other. Their motion and footprints 
were captured by a high speed video camera positioned underneath 
the walkway. The equipment was set so that failure to move to the 
other side within 9 sec was considered as a failure, not suitable 
for quantification. Three successful trials were performed for each 
mouse and the data were analyzed with the CatWalk software to 
obtain the different parameters. The principle component analysis 
was based on the average of three trials for each mouse. Some of 
the animals were tested by all three behavioral assays whenever 
time and equipment availability allowed.
Statistical analysis
Statistical comparisons between two groups were conducted 
by the two-tailed unpaired Student’s t-tests. Statistical compar-
isons among multiple groups were conducted by ANOVA tests. 
Significance was established at P < 0.05. In all graphs, error bars 
indicate SEM, and the biological replicate numbers are indicated 
on top of each bar and/or as the n numbers in the legends. The 
statistical powers for all analyses were calculated and confirmed 
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to be > 80%. The key experiments including detecting Htt level 
changes upon Mapk11/Hipk3 knockdown or knockout and the 
analysis of aggregates or LC3 puncta were confirmed by blind 
tests in which different investigators prepared/labeled the samples 
and the analyses were carried out without information exchange 
before obtaining the results. The mouse behavioral experiments 
were all performed in completely blind manner. Data were exclud-
ed when there were clear indications of artifact or experimental 
failures, such as contamination, transfection/infection failure, etc.
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